Prospects for Foamy Viral Vector Anti-HIV Gene Therapy

Stem cell gene therapy approaches for Human Immunodeficiency Virus (HIV) infection have been explored in clinical trials and several anti-HIV genes delivered by retroviral vectors were shown to block HIV replication. However, gammaretroviral and lentiviral based retroviral vectors have limitations f...

Descripción completa

Detalles Bibliográficos
Autores principales: Nalla, Arun K., Trobridge, Grant D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344253/
https://www.ncbi.nlm.nih.gov/pubmed/28536375
http://dx.doi.org/10.3390/biomedicines4020008
_version_ 1782513501028220928
author Nalla, Arun K.
Trobridge, Grant D.
author_facet Nalla, Arun K.
Trobridge, Grant D.
author_sort Nalla, Arun K.
collection PubMed
description Stem cell gene therapy approaches for Human Immunodeficiency Virus (HIV) infection have been explored in clinical trials and several anti-HIV genes delivered by retroviral vectors were shown to block HIV replication. However, gammaretroviral and lentiviral based retroviral vectors have limitations for delivery of anti-HIV genes into hematopoietic stem cells (HSC). Foamy virus vectors have several advantages including efficient delivery of transgenes into HSC in large animal models, and a potentially safer integration profile. This review focuses on novel anti-HIV transgenes and the potential of foamy virus vectors for HSC gene therapy of HIV.
format Online
Article
Text
id pubmed-5344253
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53442532017-05-23 Prospects for Foamy Viral Vector Anti-HIV Gene Therapy Nalla, Arun K. Trobridge, Grant D. Biomedicines Review Stem cell gene therapy approaches for Human Immunodeficiency Virus (HIV) infection have been explored in clinical trials and several anti-HIV genes delivered by retroviral vectors were shown to block HIV replication. However, gammaretroviral and lentiviral based retroviral vectors have limitations for delivery of anti-HIV genes into hematopoietic stem cells (HSC). Foamy virus vectors have several advantages including efficient delivery of transgenes into HSC in large animal models, and a potentially safer integration profile. This review focuses on novel anti-HIV transgenes and the potential of foamy virus vectors for HSC gene therapy of HIV. MDPI 2016-03-29 /pmc/articles/PMC5344253/ /pubmed/28536375 http://dx.doi.org/10.3390/biomedicines4020008 Text en © 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nalla, Arun K.
Trobridge, Grant D.
Prospects for Foamy Viral Vector Anti-HIV Gene Therapy
title Prospects for Foamy Viral Vector Anti-HIV Gene Therapy
title_full Prospects for Foamy Viral Vector Anti-HIV Gene Therapy
title_fullStr Prospects for Foamy Viral Vector Anti-HIV Gene Therapy
title_full_unstemmed Prospects for Foamy Viral Vector Anti-HIV Gene Therapy
title_short Prospects for Foamy Viral Vector Anti-HIV Gene Therapy
title_sort prospects for foamy viral vector anti-hiv gene therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344253/
https://www.ncbi.nlm.nih.gov/pubmed/28536375
http://dx.doi.org/10.3390/biomedicines4020008
work_keys_str_mv AT nallaarunk prospectsforfoamyviralvectorantihivgenetherapy
AT trobridgegrantd prospectsforfoamyviralvectorantihivgenetherapy

Ejemplares similares